secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001736730-25-000111
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones
--------------------------------------------------------------------------------

- Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.
- CAMP4 receives $17.5M upfront; eligible for up to $440M in milestone payments plus tiered royalties.
- CAMP4 performs research to identify and deliver lead ASO series; GSK responsible for development and commercialization.
- Tiered royalties on annual net sales range from low- to mid-single digits; royalty term per product defined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/0001736730-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000111/camp-20251217.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer